COMPOUNDS, PROCESS FOR OBTAINING THE COMPOUNDS, PHARMACEUTICAL COMPOSITION, USE OF THE COMPOUNDS AND METHOD FOR TREATING PSYCHIATRIC DISORDERS AND/OR SLEEP DISORDERS

The present invention relates to novel and inventive pharmacologically active benzimidazole derivative compounds, which surprisingly have high affinity for melatonin MT<sub>1</sub> and MT<sub>2</sub> receptors and low affinity for CYP450 complex enzymes, specially CYP1A2. The present invention also relates to novel and inventive routes of synthesis of these compounds, pharmaceutical compositions comprising the compounds and the use of these compounds in the treatment of individuals affected by psychiatric disorders and/or sleep disorders related to these receptors (specially depression, anxiety, circadian cycle disorders), in addition to process for producing the composition..

Medienart:

Patent

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Europäisches Patentamt - (2023) vom: 29. Nov. Zur Gesamtaufnahme - year:2023

Sprache:

Englisch

Beteiligte Personen:

RUCH WERNECK GUIMARÃES CRISTIANO [VerfasserIn]
FELYPE ZANETI DE AZEVEDO HATYLAS [VerfasserIn]
MASCARELLO ALESSANDRA [VerfasserIn]
WATANABE DA COSTA RENATA [VerfasserIn]
FREIRE TORRES RUSSO VALTER [VerfasserIn]
MANNOCHIO DE SOUZA RUSSO ELISA [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
C07D: Heterocyclic compounds (macromolecular compounds c0 (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2023-11-29, Last update posted on www.tib.eu: 2024-01-16, Last updated: 2024-01-19

Patentnummer:

EP3529234

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA005772788